The Open University
Genomic characterization and preclinical model development. To expand the therapeutic options for Epithelioid Hemangioendothelioma
Abstract
dc:description.abstractEpithelioid hemangioendothelioma (EHE) is an ultra-rare vascular sarcoma marked by TAZ-CAMTA1 (~90%) or YAP-TFE3 (~5%) fusion, leading to Hippo pathway dysregulation. EHE clinical behavior ranges from indolent to highly aggressive, but no biomarkers are known to predict clinical outcome at disease onset. Conventional chemotherapy has limited effectiveness and new treatment options are needed, as well as novel biomarkers of aggressiveness. This PhD project was part of a more extended project focused on preclinical investigations on EHE and involved three tasks:<br></br><br></br> i) Model generation: 3D spheroids were successfully generated from an already available patient-derived EHE cell line, both in monoculture and in co-culture with fibroblasts, revealing novel insights into the poorly understood interplay between EHE cells and stromal components, as well as providing a platform for future pharmacological and functional studies.<br></br><br></br> ii) Investigation of novel biomarkers: analysis of two independent patient series revealed a statistically significant correlation between circulating levels of Growth/differentiation factor 15 (GDF-15) and EHE aggressiveness, supporting its potential role as prognostic biomarker. Preclinical data demonstrated that GDF-15 is secreted by EHE cells and its levels are reduced following sirolimus treatment, through a mechanism involving 4E eIF4E binding protein 1 (4E-BP1) and Activating Transcription Factor 4 and 5 (ATF4/5). Additionally, microRNA (miRNA) sequencing (miRNA-seq) analysis, validated by a custom-developed digital droplet PCR (ddPCR) workflow, identified distinct alterations in circulating miRNA profiles of EHE patients, particularly in higher aggressive cases, with the clinical potential to improve risk stratification at diagnosis. <br></br><br></br> iii) Design and preclinical evaluation of novel therapeutic strategies: <i>in vitro</i> pharmacological investigations uncovered novel potential therapeutic vulnerabilities of EHE, particularly involving the Hippo and mitogen-activated protein kinase (MAPK) signaling axes, their reciprocal interplay and their cross-talk with the mammalian or mechanistic target of rapamycin (mTOR) pathway.
Degree
thesis:*- Name dc:type.qualificationname
- phd
- Level dc:type.qualificationlevel
- doctoral
- Grantor dc:publisher.institution
- The Open University
- Year dc:date.issued
- 2026
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Beretta, Alessia
Rights
- Language dc:language
- en